Article Text

Download PDFPDF
Response to: ‘Case series of acute arthritis in COVID-19 admission’ by López-González et al
  1. Elizabeth R Graef1,
  2. Jean W Liew2,
  3. Alfred HJ Kim3,
  4. Jeffrey A Sparks4
  1. 1 Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
  2. 2 Department of Medicine, Division of Rheumatology, University of Washington, Seattle, Washington, USA
  3. 3 Medicine/Rheumatology, Washington University in Saint Louis School of Medicine, Saint Louis, Missouri, USA
  4. 4 Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA
  1. Correspondence to Dr Jeffrey A Sparks, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA 02115, USA; jsparks{at}; Dr Alfred HJ Kim; akim{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read the comment on our article by López-González et al with great interest.1 2 The authors detail the presentation of four cases of acute arthritis in patients hospitalised with COVID-19 and underlying gout (three cases) or recurrent arthritis of unknown origin (one case). Although we await further reports, there have been anecdotes of newly diagnosed inflammatory arthritis in the context of COVID-19 infection, perhaps representing either a viral-associated arthritis or a reactive arthritis.3 4 However, as the authors note, common causes of acute inflammatory arthritis must continue to be considered in the differential diagnosis—these include crystal-associated arthritis, such as gout or pseudogout. Acute …

View Full Text


  • AHK and JAS are joint senior authors.

  • ERG and JWL are joint first authors.

  • Handling editor Josef S Smolen

  • Twitter @alhkim, @jeffsparks

  • AHK and JAS contributed equally.

  • ERG and JWL contributed equally.

  • Contributors ERG, JWL, AHK and JAS contributed to the conception and drafting of the article. All listed authors provided critical revision for important intellectual content and final approval.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests AHJK reports grants from National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and Rheumatology Research Foundation and personal fees from Exagen Diagnostics, Inc and GlaxoSmithKline. JAS reports grants from NIH/NIAMS/National Institute of Allergy and Infectious Diseases/Autoimmune Centers of Excellence, the Rheumatology Research Foundation, the Brigham Research Institute and the R. Bruce and Joan M. Mickey Research Scholar Fund, as well as personal fees from Bristol-Myers Squibb, Gilead, Inova, Janssen and Optum. ERG and JWL have disclosed no conflicts of interest or competing interests.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles

  • Correspondence
    María-del-Carmen López-González Maria Luisa Peral-Garrido Irene Calabuig Ernesto Tovar-Sugrañes Vega Jovani Pilar Bernabeu Raquel García-Sevila Jose-Manuel León-Ramírez Oscar Moreno-Perez Vicente Boix Joan Gil Esperanza Merino Paloma Vela Mariano Andrés